Lorenza Di Guardo

Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma

Veronica Huber, Viviana Vallacchi, Viktor Fleming et al. · Journal of Clinical Investigation · 2018 · 245 citations · Full text

Cancer Immunosurveillance, Mdsc Features, Mdsc Activity +14

Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma

Alice Indini, Lorenza Di Guardo, Carolina Cimminiello et al. · Journal of Cancer Research and Clinical Oncology · 2018 · 193 citations · Full text

Tumor Immunology, Cancer Immunosurveillance, Improved Survival +10

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

Paolo A. Ascierto, Ester Simeone, Vanna Chiarion‐Sileni et al. · Journal of Translational Medicine · 2014 · 162 citations · Full text

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

Michele Del Vecchio, Lorenza Di Guardo, Paolo A. Ascierto et al. · European Journal of Cancer · 2013 · 155 citations · Full text

Ipilimumab 3Mg/kg, Mucosal Melanoma, Medicine +8

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

Michele Maio, Riccardo Danielli, Vanna Chiarion‐Sileni et al. · Annals of Oncology · 2013 · 140 citations

Skin Cancer, Ophthalmology, Medicine +6